- LONHALA MAGNAIR is the first nebulized long-acting muscarinic antagonist (LAMA) available for the treatment of COPD in the U.S. - MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc.

Perforomist is a solution formulation of the long-acting beta 2-agonist formoterol fumarate, which is administered by inhalation via nebulization. It acts as a bronchodilator by stimulating beta 2 ...

Bitop AG Announces Start of Clinical Trial with Ectoin Inhalation Solution in Patients with Inflammation and Obstruction of the Airways | Witten, Germany, November 04, 2010 / b3c newswire / - bitop AG ...

- LONHALA MAGNAIR is the first nebulized long-acting muscarinic antagonist (LAMA) approved for the treatment of COPD in the U.S. - MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc.

Napa, Calif., (May 14, 2009) – Dey, L.P., a subsidiary of Mylan Inc. (NYSE: MYL), announced today that data from two presentations highlighting the use of Perforomist® (formoterol fumarate) Inhalation ...

Acetylcysteine 100mg/mL, 200mg/mL; soln for inhalation; preservative-free. See literature for administration of aerosol. Nebulization-face mask, mouth piece, tracheostomy: 1–10mL of 20% soln or 2–20mL ...

Perforomist (formoterol) is a brand-name drug that’s prescribed for chronic obstructive pulmonary disease (COPD) in adults. Perforomist comes as a liquid that’s inhaled with a nebulizer twice per day.

As demonstrated in preclinical studies, the inhalation solution of ISM001-055 is well tolerated with good anti-fibrotic and anti-inflammatory efficacy, favorable safety and pharmacokinetic (PK) ...

Gilead's Aztreonam for Inhalation Solution to be Reviewed by FDA Anti-Infective Drugs Advisory Committee on December 10, 2009 FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) ...

Sunovion Pharmaceuticals Inc. to Divest Xopenex® (levalbuterol HCI) Inhalation Solution (IS) to Akorn, Inc. MARLBOROUGH, Mass., Sep 30, 2014 (BUSINESS WIRE) -- Sunovion Pharmaceuticals Inc. (Sunovion) ...